Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Work In Process (2019 - 2022)

Marimed has reported Work In Process over the past 4 years, most recently at $4.1 million for Q1 2022.

  • Quarterly Work In Process rose 857.98% to $4.1 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $4.1 million through Mar 2022, up 857.98% year-over-year, with the annual reading at $4.7 million for FY2021, 895.14% up from the prior year.
  • Work In Process was $4.1 million for Q1 2022 at Marimed, down from $4.7 million in the prior quarter.
  • Over five years, Work In Process peaked at $4.7 million in Q4 2021 and troughed at $80476.0 in Q4 2019.
  • The 4-year median for Work In Process is $468377.0 (2020), against an average of $1.9 million.
  • Year-over-year, Work In Process surged 482.01% in 2020 and then soared 895.14% in 2021.
  • A 4-year view of Work In Process shows it stood at $80476.0 in 2019, then surged by 482.01% to $468377.0 in 2020, then soared by 895.14% to $4.7 million in 2021, then decreased by 12.77% to $4.1 million in 2022.
  • Per Business Quant, the three most recent readings for MRMD's Work In Process are $4.1 million (Q1 2022), $4.7 million (Q4 2021), and $3.4 million (Q3 2021).